Shares of Prime Medicine ( PRME 13.07%) are surging on Thursday. The gene-editing company's stock gained 10.5% as of 2 p.m.

Prime Medicine Inc. has announced its new preclinical program for the treatment of α1-antitrypsin deficiency (AATD). The ...

Prime Editing has potential to be best-in-class approach for AATD ---- Previously undisclosed program now emerging from within liver platform; ...

Early research shows a one-time gene therapy has potential for addressing both the liver and lung disease that patients with ...

KRRO-110 is the first RNA editing development candidate from Korro’s proprietary OPERA TM platform and is currently being evaluated in the Phase 1/2a REWRITE clinical study for AATD. Dosing of the ...

Korro Bio received U.S. FDA's orphan drug designation for investigational medicine KRRO-110 to treat Alpha-1 Antitrypsin ...

Beam Therapeutics Inc. BEAM announced positive initial safety and efficacy data from a phase I/II study, which is evaluating ...

Beam Therapeutics announced positive initial data for BEAM-302 in the Phase I/II trial in Alpha-1 Antitrypsin Deficiency (AATD).

BEAM-302 "has set the bar for efficacy in this space," William Blair analysts wrote in an investor note on Monday.

NORTH BENTON, Ohio (MyValleyTributes) – Joie Keele, born on September 15, 1963, in Parkersburg, West Virginia and passed away on March 6, 2025, in North Benton, Ohio from Alpha-1 Antitrypsin ...

Acquired DNA mutations found in the SERPINA1 gene can protect liver cells from damage in patients with alpha-1 antitrypsin ...

The small study in patients with a rare disorder that causes liver and lung damage showed the potential for precisely ...